Holen Sie sich die Stockscreener-App
118.34
2.05%
-2.48
Vorhandelsmarkt:
118.50
0.16
+0.14%
Schlusskurs vom Vortag:
$120.82
Offen:
$121.58
24-Stunden-Volumen:
1.92M
Relative Volume:
0.73
Marktkapitalisierung:
$25.84B
Einnahmen:
$819.56M
Nettoeinkommen (Verlust:
$-1.18B
KGV:
-20.60
EPS:
-5.7434
Netto-Cashflow:
$-951.64M
1W Leistung:
-3.46%
1M Leistung:
-5.91%
6M Leistung:
-17.81%
1J Leistung:
-18.60%
1-Tages-Spanne:
$116.74
$122.65
1-Wochen-Bereich:
$116.74
$127.40
52-Wochen-Spanne:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
118.34 | 25.84B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
516.34 | 130.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
801.82 | 82.55B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.11 | 72.70B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
945.82 | 59.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
365.00 | 41.29B | 5.76B | 514.49M | 1.10B | 4.4813 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2026-03-30 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-23 | Eingeleitet | Roth Capital | Buy |
| 2025-12-19 | Fortgesetzt | Truist | Buy |
| 2025-12-04 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-20 | Eingeleitet | William Blair | Outperform |
| 2025-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Eingeleitet | Jefferies | Buy |
| 2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
Goldman Sachs initiates Insmed stock coverage with buy rating, $188 target - Investing.com Canada
Insmed Incorporated (INSM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Insmed Incorporated (INSM) stock price, news, quote and history - Yahoo Finance Australia
Insmed Incorporated (INSM) latest stock news and headlines - Yahoo Finance UK
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce - TradingView
Insmed stock price target maintained at $195 by Mizuho on FDA review - Investing.com Canada
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Did FDA Priority Review of ARIKAYCE ENCORE Data Just Shift Insmed's (INSM) Investment Narrative? - Yahoo Finance
FDA priority review for Insmed's Arikayce sNDA - The Pharma Letter
Why is Insmed stock climbing today? By Investing.com - Investing.com Canada
Insmed stock rises on FDA priority review for Arikayce By Investing.com - Investing.com Canada
FDA Grants Priority Review To Insmed's SNDA For Arikayce For Treatment Of Mac Lung Disease With PDUFA Target Action Date Set For January 28, 2027 - TradingView
Insmed receives FDA priority review for ARIKAYCE - grafa.com
FDA grants priority review for Insmed’s ARIKAYCE lung disease drug By Investing.com - Investing.com Canada
INSM Looks 44.7% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
FDA grants Priority Review to Insmed's ARIKAYCE for full approval in treating MAC lung disease - Pluang
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 - Insmed Incorporated Investor Relations
Insmed Incorporated (INSM) Gets FDA Priority Review; PDUFA Jan 28, 2027 - TradingView
Insmed stock slips after strong earnings surprise and rich valuation debate - AD HOC NEWS
Insmed Stock Price Forecast. Should You Buy INSM? - StockInvest.us
Insmed Inc (INSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Is Insmed (INSM) Fully Priced After Its 296% Revenue Surge? - webull.com
The Fund Exited Insmed (INSM) After the Investment Thesis Played Out - Yahoo Finance
Insmed Expands Community Impact During Fifth Annual Global Day of Good - PR Newswire
1INSM.MI Interactive Stock Chart | INSMED INC Stock - Yahoo Finance
INSMED Inc Director Brennan David R Sells 25,000 Shares at $124 Each on September 9, 2026 - Kalkine Media
Insmed(INSM.US) Director Sells US$3.1 Million in Common Stock - Moomoo
Insmed Director Sold Shares Worth Over $3.1M - TradingView
Insmed (INSM) director sells 25,000 shares in open-market deal - Stock Titan
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now? - Zacks Investment Research
Insmed (NASDAQ: INSM) director lines up 25,000-share sale - Stock Titan
Exiting Insmed (INSM) Following Disappointing Key Drug Uptake - Yahoo Finance
Can Insmed (INSM) Still Look Reasonable After Raised Sales Guidance? - webull.com
Insmed Incorporated at Cantor Global Healthcare Conference Transcript - GuruFocus
Insmed at Cantor conference: higher sales outlook lifts growth case By Investing.com - Investing.com Australia
Why Insmed (INSM) Stock Is Up Today - Quiver Quantitative
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
Insmed rated Strong Buy with 39% upside on robu... - Pluang
Here's How Much $100 Invested In Insmed 5 Years Ago Would Be Worth Today - Benzinga
Insmed to Present Data across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 - marketscreener.com
Insmed Grants Inducement Awards to 128 New Employees - Intellectia AI
128 new employees receive stock awards from Insmed - Stock Titan
INSM Looks 38.8% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Insmed presents new respiratory drug data at ER... - Pluang
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 - PR Newswire
The top 12 companies hiring in biopharma now - BioSpace
Insmed director Sharoky sells $637,650 of Insmed stock By Investing.com - Investing.com Nigeria
Insmed director Sharoky sells $637,650 of Insmed stock - Investing.com
Do You Believe in Insmed’s INSM) Long-Term Potential Despite Short-Term Challenges? - Yahoo Finance
Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business - Yahoo Finance
Insmed Incorporated (INSM): Investor Outlook on a Biotech Pioneer with 68.87% Potential Upside - DirectorsTalk Interviews
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):